Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Background Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and d...
Guardado en:
Autores principales: | Erika Richtig, Joanna Mangana, Christian Posch, Christoph Hoeller, Julia Maria Ressler, Matthias Karasek, Lukas Koch, Rita Silmbrod, Veronica Aedo-Lopez, Helmut Kehrer, Felix Weihsengruber, Peter Koelblinger, Julian Kofler, Christine Hafner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ea3dbbcfc7aa40dd9cf2d630e1cec0b6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Publicado: (2021) -
A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
por: Megumi Kai, et al.
Publicado: (2021) -
Real-Time PCR Assay for the Detection and Quantification of Roe Deer to Detect Food Adulteration—Interlaboratory Validation Involving Laboratories in Austria, Germany, and Switzerland
por: Barbara Druml, et al.
Publicado: (2021) -
Implementation Word2Vec for Feature Expansion in Twitter Sentiment Analysis
por: Naufal Adi Nugroho, et al.
Publicado: (2021) -
Superconductivity in LiGa2Ir Heusler type compound with VEC = 16
por: Karolina Górnicka, et al.
Publicado: (2021)